The European Medicines Agency said today that it has started a rolling review of molnupiravir, an oral antiviral drug developed by Merck and Ridgeback Biotherapeutics for treating newly diagnosed COVID-19 in adults.In a statement, the EMA said its decision to start the assessment is based on preliminary findings that suggest the drug may reduce SARS-CoV-2 replication, which could play a role in preventing hospitalization and death.The agency notes that a rolling review—a tool used to speed assessment during public health emergencies—will continue until the companies have enough evidence to submit a formal authorization application.The development follow's Merck's Oct 11 announcement that it and Ridgeback had submitted an emergency use